Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
4,973
archived clinical trials in
High Cholesterol

A 12-Week Study to Assess the Efficacy Safety and Tolerability of Gemcabene in Subjects With Severe Hypertriglyceridemia
A 12-Week, Phase 2 Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy Safety and Tolerability of Gemcabene in Subjects With Severe Hypertriglyceridemia (INDIGO-1)
Status: Enrolling
Updated:  2/12/2018
Richard Lochamy, M.D.
mi
from
Junction City, KA
A 12-Week Study to Assess the Efficacy Safety and Tolerability of Gemcabene in Subjects With Severe Hypertriglyceridemia
A 12-Week, Phase 2 Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy Safety and Tolerability of Gemcabene in Subjects With Severe Hypertriglyceridemia (INDIGO-1)
Status: Enrolling
Updated: 2/12/2018
Richard Lochamy, M.D.
mi
from
Junction City, KA
Click here to add this to my saved trials
A 12-Week Study to Assess the Efficacy Safety and Tolerability of Gemcabene in Subjects With Severe Hypertriglyceridemia
A 12-Week, Phase 2 Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy Safety and Tolerability of Gemcabene in Subjects With Severe Hypertriglyceridemia (INDIGO-1)
Status: Enrolling
Updated:  2/12/2018
University of Kansas Medical Center
mi
from
Kansas City, KA
A 12-Week Study to Assess the Efficacy Safety and Tolerability of Gemcabene in Subjects With Severe Hypertriglyceridemia
A 12-Week, Phase 2 Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy Safety and Tolerability of Gemcabene in Subjects With Severe Hypertriglyceridemia (INDIGO-1)
Status: Enrolling
Updated: 2/12/2018
University of Kansas Medical Center
mi
from
Kansas City, KA
Click here to add this to my saved trials
A 12-Week Study to Assess the Efficacy Safety and Tolerability of Gemcabene in Subjects With Severe Hypertriglyceridemia
A 12-Week, Phase 2 Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy Safety and Tolerability of Gemcabene in Subjects With Severe Hypertriglyceridemia (INDIGO-1)
Status: Enrolling
Updated:  2/12/2018
L-MARC Research Center
mi
from
Louisville, KY
A 12-Week Study to Assess the Efficacy Safety and Tolerability of Gemcabene in Subjects With Severe Hypertriglyceridemia
A 12-Week, Phase 2 Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy Safety and Tolerability of Gemcabene in Subjects With Severe Hypertriglyceridemia (INDIGO-1)
Status: Enrolling
Updated: 2/12/2018
L-MARC Research Center
mi
from
Louisville, KY
Click here to add this to my saved trials
A 12-Week Study to Assess the Efficacy Safety and Tolerability of Gemcabene in Subjects With Severe Hypertriglyceridemia
A 12-Week, Phase 2 Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy Safety and Tolerability of Gemcabene in Subjects With Severe Hypertriglyceridemia (INDIGO-1)
Status: Enrolling
Updated:  2/12/2018
Clinical Trials Management LLC
mi
from
Covington, LA
A 12-Week Study to Assess the Efficacy Safety and Tolerability of Gemcabene in Subjects With Severe Hypertriglyceridemia
A 12-Week, Phase 2 Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy Safety and Tolerability of Gemcabene in Subjects With Severe Hypertriglyceridemia (INDIGO-1)
Status: Enrolling
Updated: 2/12/2018
Clinical Trials Management LLC
mi
from
Covington, LA
Click here to add this to my saved trials
A 12-Week Study to Assess the Efficacy Safety and Tolerability of Gemcabene in Subjects With Severe Hypertriglyceridemia
A 12-Week, Phase 2 Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy Safety and Tolerability of Gemcabene in Subjects With Severe Hypertriglyceridemia (INDIGO-1)
Status: Enrolling
Updated:  2/12/2018
Clinical Trials Management
mi
from
Metairie, LA
A 12-Week Study to Assess the Efficacy Safety and Tolerability of Gemcabene in Subjects With Severe Hypertriglyceridemia
A 12-Week, Phase 2 Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy Safety and Tolerability of Gemcabene in Subjects With Severe Hypertriglyceridemia (INDIGO-1)
Status: Enrolling
Updated: 2/12/2018
Clinical Trials Management
mi
from
Metairie, LA
Click here to add this to my saved trials
A 12-Week Study to Assess the Efficacy Safety and Tolerability of Gemcabene in Subjects With Severe Hypertriglyceridemia
A 12-Week, Phase 2 Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy Safety and Tolerability of Gemcabene in Subjects With Severe Hypertriglyceridemia (INDIGO-1)
Status: Enrolling
Updated:  2/12/2018
University of Maryland Medical Center
mi
from
Baltimore, MD
A 12-Week Study to Assess the Efficacy Safety and Tolerability of Gemcabene in Subjects With Severe Hypertriglyceridemia
A 12-Week, Phase 2 Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy Safety and Tolerability of Gemcabene in Subjects With Severe Hypertriglyceridemia (INDIGO-1)
Status: Enrolling
Updated: 2/12/2018
University of Maryland Medical Center
mi
from
Baltimore, MD
Click here to add this to my saved trials
A 12-Week Study to Assess the Efficacy Safety and Tolerability of Gemcabene in Subjects With Severe Hypertriglyceridemia
A 12-Week, Phase 2 Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy Safety and Tolerability of Gemcabene in Subjects With Severe Hypertriglyceridemia (INDIGO-1)
Status: Enrolling
Updated:  2/12/2018
University of Michigan Health Systems
mi
from
Ann Arbor, MI
A 12-Week Study to Assess the Efficacy Safety and Tolerability of Gemcabene in Subjects With Severe Hypertriglyceridemia
A 12-Week, Phase 2 Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy Safety and Tolerability of Gemcabene in Subjects With Severe Hypertriglyceridemia (INDIGO-1)
Status: Enrolling
Updated: 2/12/2018
University of Michigan Health Systems
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
A 12-Week Study to Assess the Efficacy Safety and Tolerability of Gemcabene in Subjects With Severe Hypertriglyceridemia
A 12-Week, Phase 2 Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy Safety and Tolerability of Gemcabene in Subjects With Severe Hypertriglyceridemia (INDIGO-1)
Status: Enrolling
Updated:  2/12/2018
Elite Clinical Research, LLC
mi
from
Jackson, MS
A 12-Week Study to Assess the Efficacy Safety and Tolerability of Gemcabene in Subjects With Severe Hypertriglyceridemia
A 12-Week, Phase 2 Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy Safety and Tolerability of Gemcabene in Subjects With Severe Hypertriglyceridemia (INDIGO-1)
Status: Enrolling
Updated: 2/12/2018
Elite Clinical Research, LLC
mi
from
Jackson, MS
Click here to add this to my saved trials
A 12-Week Study to Assess the Efficacy Safety and Tolerability of Gemcabene in Subjects With Severe Hypertriglyceridemia
A 12-Week, Phase 2 Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy Safety and Tolerability of Gemcabene in Subjects With Severe Hypertriglyceridemia (INDIGO-1)
Status: Enrolling
Updated:  2/12/2018
Clinical Research of South Nevada
mi
from
Las Vegas, NV
A 12-Week Study to Assess the Efficacy Safety and Tolerability of Gemcabene in Subjects With Severe Hypertriglyceridemia
A 12-Week, Phase 2 Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy Safety and Tolerability of Gemcabene in Subjects With Severe Hypertriglyceridemia (INDIGO-1)
Status: Enrolling
Updated: 2/12/2018
Clinical Research of South Nevada
mi
from
Las Vegas, NV
Click here to add this to my saved trials
A 12-Week Study to Assess the Efficacy Safety and Tolerability of Gemcabene in Subjects With Severe Hypertriglyceridemia
A 12-Week, Phase 2 Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy Safety and Tolerability of Gemcabene in Subjects With Severe Hypertriglyceridemia (INDIGO-1)
Status: Enrolling
Updated:  2/12/2018
CHEAR Center
mi
from
Bronx, NY
A 12-Week Study to Assess the Efficacy Safety and Tolerability of Gemcabene in Subjects With Severe Hypertriglyceridemia
A 12-Week, Phase 2 Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy Safety and Tolerability of Gemcabene in Subjects With Severe Hypertriglyceridemia (INDIGO-1)
Status: Enrolling
Updated: 2/12/2018
CHEAR Center
mi
from
Bronx, NY
Click here to add this to my saved trials
A 12-Week Study to Assess the Efficacy Safety and Tolerability of Gemcabene in Subjects With Severe Hypertriglyceridemia
A 12-Week, Phase 2 Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy Safety and Tolerability of Gemcabene in Subjects With Severe Hypertriglyceridemia (INDIGO-1)
Status: Enrolling
Updated:  2/12/2018
Advantage Clinical Trials
mi
from
Bronx, NY
A 12-Week Study to Assess the Efficacy Safety and Tolerability of Gemcabene in Subjects With Severe Hypertriglyceridemia
A 12-Week, Phase 2 Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy Safety and Tolerability of Gemcabene in Subjects With Severe Hypertriglyceridemia (INDIGO-1)
Status: Enrolling
Updated: 2/12/2018
Advantage Clinical Trials
mi
from
Bronx, NY
Click here to add this to my saved trials
A 12-Week Study to Assess the Efficacy Safety and Tolerability of Gemcabene in Subjects With Severe Hypertriglyceridemia
A 12-Week, Phase 2 Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy Safety and Tolerability of Gemcabene in Subjects With Severe Hypertriglyceridemia (INDIGO-1)
Status: Enrolling
Updated:  2/12/2018
Eastern Carolina Medical Clinic
mi
from
Benson, NC
A 12-Week Study to Assess the Efficacy Safety and Tolerability of Gemcabene in Subjects With Severe Hypertriglyceridemia
A 12-Week, Phase 2 Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy Safety and Tolerability of Gemcabene in Subjects With Severe Hypertriglyceridemia (INDIGO-1)
Status: Enrolling
Updated: 2/12/2018
Eastern Carolina Medical Clinic
mi
from
Benson, NC
Click here to add this to my saved trials
A 12-Week Study to Assess the Efficacy Safety and Tolerability of Gemcabene in Subjects With Severe Hypertriglyceridemia
A 12-Week, Phase 2 Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy Safety and Tolerability of Gemcabene in Subjects With Severe Hypertriglyceridemia (INDIGO-1)
Status: Enrolling
Updated:  2/12/2018
Physicians East, NA
mi
from
Farmville, NC
A 12-Week Study to Assess the Efficacy Safety and Tolerability of Gemcabene in Subjects With Severe Hypertriglyceridemia
A 12-Week, Phase 2 Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy Safety and Tolerability of Gemcabene in Subjects With Severe Hypertriglyceridemia (INDIGO-1)
Status: Enrolling
Updated: 2/12/2018
Physicians East, NA
mi
from
Farmville, NC
Click here to add this to my saved trials
A 12-Week Study to Assess the Efficacy Safety and Tolerability of Gemcabene in Subjects With Severe Hypertriglyceridemia
A 12-Week, Phase 2 Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy Safety and Tolerability of Gemcabene in Subjects With Severe Hypertriglyceridemia (INDIGO-1)
Status: Enrolling
Updated:  2/12/2018
Physicians East, NA
mi
from
Greenville, NC
A 12-Week Study to Assess the Efficacy Safety and Tolerability of Gemcabene in Subjects With Severe Hypertriglyceridemia
A 12-Week, Phase 2 Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy Safety and Tolerability of Gemcabene in Subjects With Severe Hypertriglyceridemia (INDIGO-1)
Status: Enrolling
Updated: 2/12/2018
Physicians East, NA
mi
from
Greenville, NC
Click here to add this to my saved trials
A 12-Week Study to Assess the Efficacy Safety and Tolerability of Gemcabene in Subjects With Severe Hypertriglyceridemia
A 12-Week, Phase 2 Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy Safety and Tolerability of Gemcabene in Subjects With Severe Hypertriglyceridemia (INDIGO-1)
Status: Enrolling
Updated:  2/12/2018
Cary Medical Clinic
mi
from
Morrisville, NC
A 12-Week Study to Assess the Efficacy Safety and Tolerability of Gemcabene in Subjects With Severe Hypertriglyceridemia
A 12-Week, Phase 2 Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy Safety and Tolerability of Gemcabene in Subjects With Severe Hypertriglyceridemia (INDIGO-1)
Status: Enrolling
Updated: 2/12/2018
Cary Medical Clinic
mi
from
Morrisville, NC
Click here to add this to my saved trials
A 12-Week Study to Assess the Efficacy Safety and Tolerability of Gemcabene in Subjects With Severe Hypertriglyceridemia
A 12-Week, Phase 2 Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy Safety and Tolerability of Gemcabene in Subjects With Severe Hypertriglyceridemia (INDIGO-1)
Status: Enrolling
Updated:  2/12/2018
Optimed Research, LTD
mi
from
Columbus, OH
A 12-Week Study to Assess the Efficacy Safety and Tolerability of Gemcabene in Subjects With Severe Hypertriglyceridemia
A 12-Week, Phase 2 Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy Safety and Tolerability of Gemcabene in Subjects With Severe Hypertriglyceridemia (INDIGO-1)
Status: Enrolling
Updated: 2/12/2018
Optimed Research, LTD
mi
from
Columbus, OH
Click here to add this to my saved trials
A 12-Week Study to Assess the Efficacy Safety and Tolerability of Gemcabene in Subjects With Severe Hypertriglyceridemia
A 12-Week, Phase 2 Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy Safety and Tolerability of Gemcabene in Subjects With Severe Hypertriglyceridemia (INDIGO-1)
Status: Enrolling
Updated:  2/12/2018
Primed Clinical Research
mi
from
Dayton, OH
A 12-Week Study to Assess the Efficacy Safety and Tolerability of Gemcabene in Subjects With Severe Hypertriglyceridemia
A 12-Week, Phase 2 Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy Safety and Tolerability of Gemcabene in Subjects With Severe Hypertriglyceridemia (INDIGO-1)
Status: Enrolling
Updated: 2/12/2018
Primed Clinical Research
mi
from
Dayton, OH
Click here to add this to my saved trials
A 12-Week Study to Assess the Efficacy Safety and Tolerability of Gemcabene in Subjects With Severe Hypertriglyceridemia
A 12-Week, Phase 2 Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy Safety and Tolerability of Gemcabene in Subjects With Severe Hypertriglyceridemia (INDIGO-1)
Status: Enrolling
Updated:  2/12/2018
Green and Seidner Family Practice Associates
mi
from
Lansdale, PA
A 12-Week Study to Assess the Efficacy Safety and Tolerability of Gemcabene in Subjects With Severe Hypertriglyceridemia
A 12-Week, Phase 2 Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy Safety and Tolerability of Gemcabene in Subjects With Severe Hypertriglyceridemia (INDIGO-1)
Status: Enrolling
Updated: 2/12/2018
Green and Seidner Family Practice Associates
mi
from
Lansdale, PA
Click here to add this to my saved trials
A 12-Week Study to Assess the Efficacy Safety and Tolerability of Gemcabene in Subjects With Severe Hypertriglyceridemia
A 12-Week, Phase 2 Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy Safety and Tolerability of Gemcabene in Subjects With Severe Hypertriglyceridemia (INDIGO-1)
Status: Enrolling
Updated:  2/12/2018
BTC of Lincoln
mi
from
Lincoln, RI
A 12-Week Study to Assess the Efficacy Safety and Tolerability of Gemcabene in Subjects With Severe Hypertriglyceridemia
A 12-Week, Phase 2 Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy Safety and Tolerability of Gemcabene in Subjects With Severe Hypertriglyceridemia (INDIGO-1)
Status: Enrolling
Updated: 2/12/2018
BTC of Lincoln
mi
from
Lincoln, RI
Click here to add this to my saved trials
A 12-Week Study to Assess the Efficacy Safety and Tolerability of Gemcabene in Subjects With Severe Hypertriglyceridemia
A 12-Week, Phase 2 Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy Safety and Tolerability of Gemcabene in Subjects With Severe Hypertriglyceridemia (INDIGO-1)
Status: Enrolling
Updated:  2/12/2018
Carolinas Research Partners, LLC
mi
from
Rock Hill, SC
A 12-Week Study to Assess the Efficacy Safety and Tolerability of Gemcabene in Subjects With Severe Hypertriglyceridemia
A 12-Week, Phase 2 Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy Safety and Tolerability of Gemcabene in Subjects With Severe Hypertriglyceridemia (INDIGO-1)
Status: Enrolling
Updated: 2/12/2018
Carolinas Research Partners, LLC
mi
from
Rock Hill, SC
Click here to add this to my saved trials
A 12-Week Study to Assess the Efficacy Safety and Tolerability of Gemcabene in Subjects With Severe Hypertriglyceridemia
A 12-Week, Phase 2 Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy Safety and Tolerability of Gemcabene in Subjects With Severe Hypertriglyceridemia (INDIGO-1)
Status: Enrolling
Updated:  2/12/2018
Airline Complete Healthcare
mi
from
Houston, TX
A 12-Week Study to Assess the Efficacy Safety and Tolerability of Gemcabene in Subjects With Severe Hypertriglyceridemia
A 12-Week, Phase 2 Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy Safety and Tolerability of Gemcabene in Subjects With Severe Hypertriglyceridemia (INDIGO-1)
Status: Enrolling
Updated: 2/12/2018
Airline Complete Healthcare
mi
from
Houston, TX
Click here to add this to my saved trials
A 12-Week Study to Assess the Efficacy Safety and Tolerability of Gemcabene in Subjects With Severe Hypertriglyceridemia
A 12-Week, Phase 2 Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy Safety and Tolerability of Gemcabene in Subjects With Severe Hypertriglyceridemia (INDIGO-1)
Status: Enrolling
Updated:  2/12/2018
Sante Clinical Research
mi
from
Kerrville, TX
A 12-Week Study to Assess the Efficacy Safety and Tolerability of Gemcabene in Subjects With Severe Hypertriglyceridemia
A 12-Week, Phase 2 Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy Safety and Tolerability of Gemcabene in Subjects With Severe Hypertriglyceridemia (INDIGO-1)
Status: Enrolling
Updated: 2/12/2018
Sante Clinical Research
mi
from
Kerrville, TX
Click here to add this to my saved trials
A 12-Week Study to Assess the Efficacy Safety and Tolerability of Gemcabene in Subjects With Severe Hypertriglyceridemia
A 12-Week, Phase 2 Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy Safety and Tolerability of Gemcabene in Subjects With Severe Hypertriglyceridemia (INDIGO-1)
Status: Enrolling
Updated:  2/12/2018
FMC Science
mi
from
Lampasas, TX
A 12-Week Study to Assess the Efficacy Safety and Tolerability of Gemcabene in Subjects With Severe Hypertriglyceridemia
A 12-Week, Phase 2 Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy Safety and Tolerability of Gemcabene in Subjects With Severe Hypertriglyceridemia (INDIGO-1)
Status: Enrolling
Updated: 2/12/2018
FMC Science
mi
from
Lampasas, TX
Click here to add this to my saved trials
A 12-Week Study to Assess the Efficacy Safety and Tolerability of Gemcabene in Subjects With Severe Hypertriglyceridemia
A 12-Week, Phase 2 Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy Safety and Tolerability of Gemcabene in Subjects With Severe Hypertriglyceridemia (INDIGO-1)
Status: Enrolling
Updated:  2/12/2018
Clinical Investigations of Texas
mi
from
Plano, TX
A 12-Week Study to Assess the Efficacy Safety and Tolerability of Gemcabene in Subjects With Severe Hypertriglyceridemia
A 12-Week, Phase 2 Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy Safety and Tolerability of Gemcabene in Subjects With Severe Hypertriglyceridemia (INDIGO-1)
Status: Enrolling
Updated: 2/12/2018
Clinical Investigations of Texas
mi
from
Plano, TX
Click here to add this to my saved trials
A 12-Week Study to Assess the Efficacy Safety and Tolerability of Gemcabene in Subjects With Severe Hypertriglyceridemia
A 12-Week, Phase 2 Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy Safety and Tolerability of Gemcabene in Subjects With Severe Hypertriglyceridemia (INDIGO-1)
Status: Enrolling
Updated:  2/12/2018
Sun Research Institute
mi
from
San Antonio, TX
A 12-Week Study to Assess the Efficacy Safety and Tolerability of Gemcabene in Subjects With Severe Hypertriglyceridemia
A 12-Week, Phase 2 Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy Safety and Tolerability of Gemcabene in Subjects With Severe Hypertriglyceridemia (INDIGO-1)
Status: Enrolling
Updated: 2/12/2018
Sun Research Institute
mi
from
San Antonio, TX
Click here to add this to my saved trials
A 12-Week Study to Assess the Efficacy Safety and Tolerability of Gemcabene in Subjects With Severe Hypertriglyceridemia
A 12-Week, Phase 2 Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy Safety and Tolerability of Gemcabene in Subjects With Severe Hypertriglyceridemia (INDIGO-1)
Status: Enrolling
Updated:  2/12/2018
Clinical Investigation Specialists
mi
from
Kenosha, WI
A 12-Week Study to Assess the Efficacy Safety and Tolerability of Gemcabene in Subjects With Severe Hypertriglyceridemia
A 12-Week, Phase 2 Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy Safety and Tolerability of Gemcabene in Subjects With Severe Hypertriglyceridemia (INDIGO-1)
Status: Enrolling
Updated: 2/12/2018
Clinical Investigation Specialists
mi
from
Kenosha, WI
Click here to add this to my saved trials
A 12-Week Study to Assess the Efficacy Safety and Tolerability of Gemcabene in Subjects With Severe Hypertriglyceridemia
A 12-Week, Phase 2 Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy Safety and Tolerability of Gemcabene in Subjects With Severe Hypertriglyceridemia (INDIGO-1)
Status: Enrolling
Updated:  2/12/2018
Ecogene-21
mi
from
Chicoutimi,
A 12-Week Study to Assess the Efficacy Safety and Tolerability of Gemcabene in Subjects With Severe Hypertriglyceridemia
A 12-Week, Phase 2 Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy Safety and Tolerability of Gemcabene in Subjects With Severe Hypertriglyceridemia (INDIGO-1)
Status: Enrolling
Updated: 2/12/2018
Ecogene-21
mi
from
Chicoutimi,
Click here to add this to my saved trials
Vascular and Lipid Effects of Omega-3 Fatty Acids in People With Moderately Elevated Triglycerides
Omacor: Measures of Endothelial Function and triGlyceride Alteration
Status: Enrolling
Updated:  2/13/2018
Penn State University - General Clinical Research Center
mi
from
University Park, PA
Vascular and Lipid Effects of Omega-3 Fatty Acids in People With Moderately Elevated Triglycerides
Omacor: Measures of Endothelial Function and triGlyceride Alteration
Status: Enrolling
Updated: 2/13/2018
Penn State University - General Clinical Research Center
mi
from
University Park, PA
Click here to add this to my saved trials
A Study of Evacetrapib (LY2484595) in Participants With High Cholesterol
The Addition of Evacetrapib to Atorvastatin Compared to Placebo, High Intensity Atorvastatin, and Atorvastatin With Ezetimibe to Evaluate LDL-C Lowering in Patients With Primary Hyperlipidemia - The ACCENTUATE Study
Status: Enrolling
Updated:  2/18/2018
Heart Center Research, Llc
mi
from
Huntsville, AL
A Study of Evacetrapib (LY2484595) in Participants With High Cholesterol
The Addition of Evacetrapib to Atorvastatin Compared to Placebo, High Intensity Atorvastatin, and Atorvastatin With Ezetimibe to Evaluate LDL-C Lowering in Patients With Primary Hyperlipidemia - The ACCENTUATE Study
Status: Enrolling
Updated: 2/18/2018
Heart Center Research, Llc
mi
from
Huntsville, AL
Click here to add this to my saved trials
A Study of Evacetrapib (LY2484595) in Participants With High Cholesterol
The Addition of Evacetrapib to Atorvastatin Compared to Placebo, High Intensity Atorvastatin, and Atorvastatin With Ezetimibe to Evaluate LDL-C Lowering in Patients With Primary Hyperlipidemia - The ACCENTUATE Study
Status: Enrolling
Updated:  2/18/2018
Desert Clinical Research
mi
from
Mesa, AZ
A Study of Evacetrapib (LY2484595) in Participants With High Cholesterol
The Addition of Evacetrapib to Atorvastatin Compared to Placebo, High Intensity Atorvastatin, and Atorvastatin With Ezetimibe to Evaluate LDL-C Lowering in Patients With Primary Hyperlipidemia - The ACCENTUATE Study
Status: Enrolling
Updated: 2/18/2018
Desert Clinical Research
mi
from
Mesa, AZ
Click here to add this to my saved trials
A Study of Evacetrapib (LY2484595) in Participants With High Cholesterol
The Addition of Evacetrapib to Atorvastatin Compared to Placebo, High Intensity Atorvastatin, and Atorvastatin With Ezetimibe to Evaluate LDL-C Lowering in Patients With Primary Hyperlipidemia - The ACCENTUATE Study
Status: Enrolling
Updated:  2/18/2018
Central Phoenix Medical Clinic
mi
from
Phoenix, AZ
A Study of Evacetrapib (LY2484595) in Participants With High Cholesterol
The Addition of Evacetrapib to Atorvastatin Compared to Placebo, High Intensity Atorvastatin, and Atorvastatin With Ezetimibe to Evaluate LDL-C Lowering in Patients With Primary Hyperlipidemia - The ACCENTUATE Study
Status: Enrolling
Updated: 2/18/2018
Central Phoenix Medical Clinic
mi
from
Phoenix, AZ
Click here to add this to my saved trials
A Study of Evacetrapib (LY2484595) in Participants With High Cholesterol
The Addition of Evacetrapib to Atorvastatin Compared to Placebo, High Intensity Atorvastatin, and Atorvastatin With Ezetimibe to Evaluate LDL-C Lowering in Patients With Primary Hyperlipidemia - The ACCENTUATE Study
Status: Enrolling
Updated:  2/18/2018
Advanced Clinical Research
mi
from
Carmichael, CA
A Study of Evacetrapib (LY2484595) in Participants With High Cholesterol
The Addition of Evacetrapib to Atorvastatin Compared to Placebo, High Intensity Atorvastatin, and Atorvastatin With Ezetimibe to Evaluate LDL-C Lowering in Patients With Primary Hyperlipidemia - The ACCENTUATE Study
Status: Enrolling
Updated: 2/18/2018
Advanced Clinical Research
mi
from
Carmichael, CA
Click here to add this to my saved trials
A Study of Evacetrapib (LY2484595) in Participants With High Cholesterol
The Addition of Evacetrapib to Atorvastatin Compared to Placebo, High Intensity Atorvastatin, and Atorvastatin With Ezetimibe to Evaluate LDL-C Lowering in Patients With Primary Hyperlipidemia - The ACCENTUATE Study
Status: Enrolling
Updated:  2/18/2018
Tooraj Joseph Raoof M.D., Inc.
mi
from
Encino, CA
A Study of Evacetrapib (LY2484595) in Participants With High Cholesterol
The Addition of Evacetrapib to Atorvastatin Compared to Placebo, High Intensity Atorvastatin, and Atorvastatin With Ezetimibe to Evaluate LDL-C Lowering in Patients With Primary Hyperlipidemia - The ACCENTUATE Study
Status: Enrolling
Updated: 2/18/2018
Tooraj Joseph Raoof M.D., Inc.
mi
from
Encino, CA
Click here to add this to my saved trials
A Study of Evacetrapib (LY2484595) in Participants With High Cholesterol
The Addition of Evacetrapib to Atorvastatin Compared to Placebo, High Intensity Atorvastatin, and Atorvastatin With Ezetimibe to Evaluate LDL-C Lowering in Patients With Primary Hyperlipidemia - The ACCENTUATE Study
Status: Enrolling
Updated:  2/18/2018
Irvine Clinical Research Center
mi
from
Irvine, CA
A Study of Evacetrapib (LY2484595) in Participants With High Cholesterol
The Addition of Evacetrapib to Atorvastatin Compared to Placebo, High Intensity Atorvastatin, and Atorvastatin With Ezetimibe to Evaluate LDL-C Lowering in Patients With Primary Hyperlipidemia - The ACCENTUATE Study
Status: Enrolling
Updated: 2/18/2018
Irvine Clinical Research Center
mi
from
Irvine, CA
Click here to add this to my saved trials
A Study of Evacetrapib (LY2484595) in Participants With High Cholesterol
The Addition of Evacetrapib to Atorvastatin Compared to Placebo, High Intensity Atorvastatin, and Atorvastatin With Ezetimibe to Evaluate LDL-C Lowering in Patients With Primary Hyperlipidemia - The ACCENTUATE Study
Status: Enrolling
Updated:  2/18/2018
VA Long Beach Healthcare System
mi
from
Long Beach, CA
A Study of Evacetrapib (LY2484595) in Participants With High Cholesterol
The Addition of Evacetrapib to Atorvastatin Compared to Placebo, High Intensity Atorvastatin, and Atorvastatin With Ezetimibe to Evaluate LDL-C Lowering in Patients With Primary Hyperlipidemia - The ACCENTUATE Study
Status: Enrolling
Updated: 2/18/2018
VA Long Beach Healthcare System
mi
from
Long Beach, CA
Click here to add this to my saved trials
A Study of Evacetrapib (LY2484595) in Participants With High Cholesterol
The Addition of Evacetrapib to Atorvastatin Compared to Placebo, High Intensity Atorvastatin, and Atorvastatin With Ezetimibe to Evaluate LDL-C Lowering in Patients With Primary Hyperlipidemia - The ACCENTUATE Study
Status: Enrolling
Updated:  2/18/2018
Rancho Cucamonga Clinical
mi
from
Rancho Cucamonga, CA
A Study of Evacetrapib (LY2484595) in Participants With High Cholesterol
The Addition of Evacetrapib to Atorvastatin Compared to Placebo, High Intensity Atorvastatin, and Atorvastatin With Ezetimibe to Evaluate LDL-C Lowering in Patients With Primary Hyperlipidemia - The ACCENTUATE Study
Status: Enrolling
Updated: 2/18/2018
Rancho Cucamonga Clinical
mi
from
Rancho Cucamonga, CA
Click here to add this to my saved trials
A Study of Evacetrapib (LY2484595) in Participants With High Cholesterol
The Addition of Evacetrapib to Atorvastatin Compared to Placebo, High Intensity Atorvastatin, and Atorvastatin With Ezetimibe to Evaluate LDL-C Lowering in Patients With Primary Hyperlipidemia - The ACCENTUATE Study
Status: Enrolling
Updated:  2/18/2018
Encompass Clinical Research
mi
from
Spring Valley, CA
A Study of Evacetrapib (LY2484595) in Participants With High Cholesterol
The Addition of Evacetrapib to Atorvastatin Compared to Placebo, High Intensity Atorvastatin, and Atorvastatin With Ezetimibe to Evaluate LDL-C Lowering in Patients With Primary Hyperlipidemia - The ACCENTUATE Study
Status: Enrolling
Updated: 2/18/2018
Encompass Clinical Research
mi
from
Spring Valley, CA
Click here to add this to my saved trials
A Study of Evacetrapib (LY2484595) in Participants With High Cholesterol
The Addition of Evacetrapib to Atorvastatin Compared to Placebo, High Intensity Atorvastatin, and Atorvastatin With Ezetimibe to Evaluate LDL-C Lowering in Patients With Primary Hyperlipidemia - The ACCENTUATE Study
Status: Enrolling
Updated:  2/18/2018
University Clinical Investigators
mi
from
Tustin, CA
A Study of Evacetrapib (LY2484595) in Participants With High Cholesterol
The Addition of Evacetrapib to Atorvastatin Compared to Placebo, High Intensity Atorvastatin, and Atorvastatin With Ezetimibe to Evaluate LDL-C Lowering in Patients With Primary Hyperlipidemia - The ACCENTUATE Study
Status: Enrolling
Updated: 2/18/2018
University Clinical Investigators
mi
from
Tustin, CA
Click here to add this to my saved trials
A Study of Evacetrapib (LY2484595) in Participants With High Cholesterol
The Addition of Evacetrapib to Atorvastatin Compared to Placebo, High Intensity Atorvastatin, and Atorvastatin With Ezetimibe to Evaluate LDL-C Lowering in Patients With Primary Hyperlipidemia - The ACCENTUATE Study
Status: Enrolling
Updated:  2/18/2018
Diablo Clinical Research Inc
mi
from
Walnut creek, CA
A Study of Evacetrapib (LY2484595) in Participants With High Cholesterol
The Addition of Evacetrapib to Atorvastatin Compared to Placebo, High Intensity Atorvastatin, and Atorvastatin With Ezetimibe to Evaluate LDL-C Lowering in Patients With Primary Hyperlipidemia - The ACCENTUATE Study
Status: Enrolling
Updated: 2/18/2018
Diablo Clinical Research Inc
mi
from
Walnut creek, CA
Click here to add this to my saved trials
A Study of Evacetrapib (LY2484595) in Participants With High Cholesterol
The Addition of Evacetrapib to Atorvastatin Compared to Placebo, High Intensity Atorvastatin, and Atorvastatin With Ezetimibe to Evaluate LDL-C Lowering in Patients With Primary Hyperlipidemia - The ACCENTUATE Study
Status: Enrolling
Updated:  2/18/2018
University of Colorado Health Sciences Ctr.
mi
from
Aurora, CO
A Study of Evacetrapib (LY2484595) in Participants With High Cholesterol
The Addition of Evacetrapib to Atorvastatin Compared to Placebo, High Intensity Atorvastatin, and Atorvastatin With Ezetimibe to Evaluate LDL-C Lowering in Patients With Primary Hyperlipidemia - The ACCENTUATE Study
Status: Enrolling
Updated: 2/18/2018
University of Colorado Health Sciences Ctr.
mi
from
Aurora, CO
Click here to add this to my saved trials
A Study of Evacetrapib (LY2484595) in Participants With High Cholesterol
The Addition of Evacetrapib to Atorvastatin Compared to Placebo, High Intensity Atorvastatin, and Atorvastatin With Ezetimibe to Evaluate LDL-C Lowering in Patients With Primary Hyperlipidemia - The ACCENTUATE Study
Status: Enrolling
Updated:  2/18/2018
Cardiac Research
mi
from
Colorado Springs, CO
A Study of Evacetrapib (LY2484595) in Participants With High Cholesterol
The Addition of Evacetrapib to Atorvastatin Compared to Placebo, High Intensity Atorvastatin, and Atorvastatin With Ezetimibe to Evaluate LDL-C Lowering in Patients With Primary Hyperlipidemia - The ACCENTUATE Study
Status: Enrolling
Updated: 2/18/2018
Cardiac Research
mi
from
Colorado Springs, CO
Click here to add this to my saved trials
A Study of Evacetrapib (LY2484595) in Participants With High Cholesterol
The Addition of Evacetrapib to Atorvastatin Compared to Placebo, High Intensity Atorvastatin, and Atorvastatin With Ezetimibe to Evaluate LDL-C Lowering in Patients With Primary Hyperlipidemia - The ACCENTUATE Study
Status: Enrolling
Updated:  2/18/2018
Zasa Clinical Research
mi
from
Boynton Beach, FL
A Study of Evacetrapib (LY2484595) in Participants With High Cholesterol
The Addition of Evacetrapib to Atorvastatin Compared to Placebo, High Intensity Atorvastatin, and Atorvastatin With Ezetimibe to Evaluate LDL-C Lowering in Patients With Primary Hyperlipidemia - The ACCENTUATE Study
Status: Enrolling
Updated: 2/18/2018
Zasa Clinical Research
mi
from
Boynton Beach, FL
Click here to add this to my saved trials
A Study of Evacetrapib (LY2484595) in Participants With High Cholesterol
The Addition of Evacetrapib to Atorvastatin Compared to Placebo, High Intensity Atorvastatin, and Atorvastatin With Ezetimibe to Evaluate LDL-C Lowering in Patients With Primary Hyperlipidemia - The ACCENTUATE Study
Status: Enrolling
Updated:  2/18/2018
Cardiology Research Assoc.
mi
from
Daytona Beach, FL
A Study of Evacetrapib (LY2484595) in Participants With High Cholesterol
The Addition of Evacetrapib to Atorvastatin Compared to Placebo, High Intensity Atorvastatin, and Atorvastatin With Ezetimibe to Evaluate LDL-C Lowering in Patients With Primary Hyperlipidemia - The ACCENTUATE Study
Status: Enrolling
Updated: 2/18/2018
Cardiology Research Assoc.
mi
from
Daytona Beach, FL
Click here to add this to my saved trials
A Study of Evacetrapib (LY2484595) in Participants With High Cholesterol
The Addition of Evacetrapib to Atorvastatin Compared to Placebo, High Intensity Atorvastatin, and Atorvastatin With Ezetimibe to Evaluate LDL-C Lowering in Patients With Primary Hyperlipidemia - The ACCENTUATE Study
Status: Enrolling
Updated:  2/18/2018
Avail Clinical Research
mi
from
DeLand, FL
A Study of Evacetrapib (LY2484595) in Participants With High Cholesterol
The Addition of Evacetrapib to Atorvastatin Compared to Placebo, High Intensity Atorvastatin, and Atorvastatin With Ezetimibe to Evaluate LDL-C Lowering in Patients With Primary Hyperlipidemia - The ACCENTUATE Study
Status: Enrolling
Updated: 2/18/2018
Avail Clinical Research
mi
from
DeLand, FL
Click here to add this to my saved trials
A Study of Evacetrapib (LY2484595) in Participants With High Cholesterol
The Addition of Evacetrapib to Atorvastatin Compared to Placebo, High Intensity Atorvastatin, and Atorvastatin With Ezetimibe to Evaluate LDL-C Lowering in Patients With Primary Hyperlipidemia - The ACCENTUATE Study
Status: Enrolling
Updated:  2/18/2018
Alan Graff, MD, PA
mi
from
Fort Lauderdale, FL
A Study of Evacetrapib (LY2484595) in Participants With High Cholesterol
The Addition of Evacetrapib to Atorvastatin Compared to Placebo, High Intensity Atorvastatin, and Atorvastatin With Ezetimibe to Evaluate LDL-C Lowering in Patients With Primary Hyperlipidemia - The ACCENTUATE Study
Status: Enrolling
Updated: 2/18/2018
Alan Graff, MD, PA
mi
from
Fort Lauderdale, FL
Click here to add this to my saved trials
A Study of Evacetrapib (LY2484595) in Participants With High Cholesterol
The Addition of Evacetrapib to Atorvastatin Compared to Placebo, High Intensity Atorvastatin, and Atorvastatin With Ezetimibe to Evaluate LDL-C Lowering in Patients With Primary Hyperlipidemia - The ACCENTUATE Study
Status: Enrolling
Updated:  2/18/2018
Nature Coast Clinical Research
mi
from
Inverness, FL
A Study of Evacetrapib (LY2484595) in Participants With High Cholesterol
The Addition of Evacetrapib to Atorvastatin Compared to Placebo, High Intensity Atorvastatin, and Atorvastatin With Ezetimibe to Evaluate LDL-C Lowering in Patients With Primary Hyperlipidemia - The ACCENTUATE Study
Status: Enrolling
Updated: 2/18/2018
Nature Coast Clinical Research
mi
from
Inverness, FL
Click here to add this to my saved trials
A Study of Evacetrapib (LY2484595) in Participants With High Cholesterol
The Addition of Evacetrapib to Atorvastatin Compared to Placebo, High Intensity Atorvastatin, and Atorvastatin With Ezetimibe to Evaluate LDL-C Lowering in Patients With Primary Hyperlipidemia - The ACCENTUATE Study
Status: Enrolling
Updated:  2/18/2018
Suncoast Research Group, LLC
mi
from
Miami, FL
A Study of Evacetrapib (LY2484595) in Participants With High Cholesterol
The Addition of Evacetrapib to Atorvastatin Compared to Placebo, High Intensity Atorvastatin, and Atorvastatin With Ezetimibe to Evaluate LDL-C Lowering in Patients With Primary Hyperlipidemia - The ACCENTUATE Study
Status: Enrolling
Updated: 2/18/2018
Suncoast Research Group, LLC
mi
from
Miami, FL
Click here to add this to my saved trials
A Study of Evacetrapib (LY2484595) in Participants With High Cholesterol
The Addition of Evacetrapib to Atorvastatin Compared to Placebo, High Intensity Atorvastatin, and Atorvastatin With Ezetimibe to Evaluate LDL-C Lowering in Patients With Primary Hyperlipidemia - The ACCENTUATE Study
Status: Enrolling
Updated:  2/18/2018
Progressive Medical Research
mi
from
Port Orange, FL
A Study of Evacetrapib (LY2484595) in Participants With High Cholesterol
The Addition of Evacetrapib to Atorvastatin Compared to Placebo, High Intensity Atorvastatin, and Atorvastatin With Ezetimibe to Evaluate LDL-C Lowering in Patients With Primary Hyperlipidemia - The ACCENTUATE Study
Status: Enrolling
Updated: 2/18/2018
Progressive Medical Research
mi
from
Port Orange, FL
Click here to add this to my saved trials
A Study of Evacetrapib (LY2484595) in Participants With High Cholesterol
The Addition of Evacetrapib to Atorvastatin Compared to Placebo, High Intensity Atorvastatin, and Atorvastatin With Ezetimibe to Evaluate LDL-C Lowering in Patients With Primary Hyperlipidemia - The ACCENTUATE Study
Status: Enrolling
Updated:  2/18/2018
Cardiology Partners Clinical Research Institute
mi
from
Wellington, FL
A Study of Evacetrapib (LY2484595) in Participants With High Cholesterol
The Addition of Evacetrapib to Atorvastatin Compared to Placebo, High Intensity Atorvastatin, and Atorvastatin With Ezetimibe to Evaluate LDL-C Lowering in Patients With Primary Hyperlipidemia - The ACCENTUATE Study
Status: Enrolling
Updated: 2/18/2018
Cardiology Partners Clinical Research Institute
mi
from
Wellington, FL
Click here to add this to my saved trials
A Study of Evacetrapib (LY2484595) in Participants With High Cholesterol
The Addition of Evacetrapib to Atorvastatin Compared to Placebo, High Intensity Atorvastatin, and Atorvastatin With Ezetimibe to Evaluate LDL-C Lowering in Patients With Primary Hyperlipidemia - The ACCENTUATE Study
Status: Enrolling
Updated:  2/18/2018
Georgia Heart Specialists
mi
from
Covington, GA
A Study of Evacetrapib (LY2484595) in Participants With High Cholesterol
The Addition of Evacetrapib to Atorvastatin Compared to Placebo, High Intensity Atorvastatin, and Atorvastatin With Ezetimibe to Evaluate LDL-C Lowering in Patients With Primary Hyperlipidemia - The ACCENTUATE Study
Status: Enrolling
Updated: 2/18/2018
Georgia Heart Specialists
mi
from
Covington, GA
Click here to add this to my saved trials